Satirical media outlet, The Onion, on Lilly’s new insulin that “doesn’t work on poor people.”

Cardiology Guidelines

Questioning Antihypertensives for Older Patients

When clinicians find that an older hospitalized patient has elevated blood pressure, their next step is often to initiate antihypertensive treatment, but a new JAMA Internal Medicine study suggests that many of these patients would be better off having their BPs left unmanaged.

Researchers from Beth Israel, UCSF, and the VA analyzed data from 66k older VA patients hospitalized for non-cardiac conditions who experienced elevated BPs during their first 48 hours of hospitalization.

A sizable 21.3% of the patients (14k) received intensive BP treatments within their first 48 hours. 

• Those patients were far more likely to experience at least one negative outcome (8.7% vs. 6.9%; weighted odds ratio: 1.28)
• Their risk of negative outcomes was especially high if they received intravenous antihypertensives (weighted odds ratio: 1.90)
• And the patients showed no clear benefits from receiving early and intensive BP treatments

Early treatment decisions also appeared to have a major impact on patients’ longer-term BP treatment regimens, as those treated within the first 48 hours ended up receiving far more antihypertensive doses than patients whose treatments started after 48 hours (mean additional doses: 6.1 vs. 1.6).

These results join a growing field of retrospective and observational studies that similarly highlighted the risks of intensive BP therapy, prompting the authors to call for the first RCTs on inpatient BP treatment. 

The authors also advised against initiating intensive BP treatments for non-cardiac patients unless there’s evidence of organ damage, and especially avoiding intravenous antihypertensives, while shifting clinical focus to managing the underlying causes of high BP.

Although many seemed to agree that clinicians should rethink how and when they treat elevated BP in these patients, others cautioned that these results might be biased (e.g. sicker patients are more likely to receive early/intense BP treatment) and aren’t strong enough to justify major changes in BP treatment policies on their own.

The Takeaway
One could make the case that this study is both clinically logical and at risk of statistical bias, and although a RCT would help settle both arguments, a BP RCT doesn’t appear to be coming soon.

With that, clinicians might benefit from acknowledging that early and intensive BP treatment appears to be associated with poor outcomes in non-cardiac patients (retrospectively, anyway), and making sure their BP treatment decisions are only as early and intense as each patient specifically requires.

Imaging AI + Calcium Scoring for Heart Attack Prevention

See how CCTA AI combines with CAC scoring to transform preventive heart care in this on-demand webinar featuring world-renowned prevention expert Dr. Arthur Agatston (author of the South Beach Diet, creator of the Agatston score), Cleerly founder Dr. James Min, and CMO Dr. James P. Earls.

AI Echo Copilot – The Future of Echocardiography

New technology from Us2ai called Us2.connect allows you to add AI automation to any echo device. Any echo machine can now have 100% automated reporting with disease detection and editable measurements – all generated in realtime as you scan.

The First Step to Coronary Artery Disease Diagnosis

HeartFlow’s new RoadMap Analysis solution allows CT readers to accurately, efficiently, and consistently identify stenoses in the coronary arteries. See how RoadMap Analysis’ visual and quantitative insights into the narrowing of all major coronary arteries helps readers evaluate coronary CT angiograms before determining the need for an FFRCT.

The Wire

• Obicetrapib’s LDL-C Impact: A new study highlighted the LDL-C-lowering potential of NewAmsterdam Pharma’s obicetrapib when used as an adjunct to high-intensity statins. The ROSE2 trial had 97 statin-taking patients with elevated LDL-C take either 10 mg obicetrapib plus 10 mg ezetimibe, 10 mg obicetrapib, or a placebo for 12 weeks. The two obicetrapib groups achieved far greater respective LDL-C reductions (63.4% & 43.5% vs. placebo’s 6.35%), while patients taking both obicetrapib and ezetimibe commonly achieved LDL-C levels of <100, <70, and <55 mg/dL (100%, 93.5%, and 87.1%).

• Abiomed Impella Pump Recall: After 179 complaints and three injuries, Abiomed has issued a FDA Class I recall (the most serious recall level) for its Impella 5.5 with SmartAssist pumps distributed in the US between September 2021 and March 2023 (466 units). Abiomed’s Impella pump is intended to temporarily support the heart’s pumping functions, but the recall reveals that purge fluid leaks could cause the pump to fail, putting patients at risk of further injury or death. 

• ECG AI for CKD Screening: Cedars-Sinai’s Smidt Heart Institute published yet another impressive cardiology AI study, this time showing that ECGs can be used to screen for undetected chronic kidney disease (here’s some of their previous AI studies). After training with ECG data from 111k patients, the AI model was able to detect which of 312k patients from an external cohort had CKD (0.701-0.709 AUCs), performing even better with patients younger than 60 years-old (0.777-0.784 AUCs).

• Karoo Health’s Cardiac VBC Funding: Cardiology value-based care enablement startup Karoo Health emerged this week, with a $3.4M Seed round to support its summer 2023 launch in the Southwest US and future expansion. Karoo equips dedicated on-site and virtual care teams with “value-based technology” (online interface, mobile app, telemedicine, wearables) to help cardiology networks, health plans, and health systems transition to outcomes-driven initiatives and contracts.

• A Case for Early PCSK9i Therapy: Data presented by Amgen at National Lipid Association 2023 showed that early initiation of PCSK9i therapy after MACE reduces subsequent MACE risks, although PCSK9i is rarely initiated early. PCSK9i therapy was initiated a median of 786 days after MACE (N=59k), with far more patients beginning therapy >360 days or 181-360 days after MACE (55.2% & 16%) than ≤30 days or 31-90 days after MACE (7% & 11%). Individuals who began PCSK9i therapy early were less likely to experience subsequent MACE and had longer periods between their index and subsequent MACE.

• UPenn Guides CPR with Rescue TEE: Penn Medicine is conducting a trial to determine if a new transesophageal echo-based device, called Rescue TEE, is able to improve cardiac arrest resuscitation outcomes. The Rescue TEE captures and transmits live ultrasound images of the heart during resuscitation, allowing doctors to quickly identify the cause of a cardiac arrest and confirm whether CPR is being performed in the correct area above each patient’s heart. Penn clinicians have already used Rescue TEE in 100 cardiac arrest cases.

• Sparrow’s Stethophone Clearance: Sparrow BioAcoustics announced the FDA clearance of its Stethophone software, which allows medical professionals to capture, analyze, and share cardiovascular and pulmonary sound data – simply by holding an enabled smartphone to a patient’s chest. The Stethophone app uses advanced acoustic processing to allow smartphones’ internal microphone to capture a range of cardiac markers (gallops, murmurs, and arrhythmias) and detect “cardiac and pulmonary symptoms, wherever they occur.”

• Compounded Semaglutide Warning: The FDA warned patients and clinicians to avoid using compounded semaglutide medicines as replacements for the popular (and scarce) weight loss and diabetes drugs: Ozempic, Rybelsus, and Wegovy. Compounded medications are permitted during drug shortages, even if they aren’t FDA-approved, but the FDA has received reports of adverse events related to compounded semaglutide replacements and is concerned that they might use unproven active ingredients.

• Torsemide & Furosemide Match Again: The randomized TRANSFORM-HF trial already found that furosemide and torsemide have comparable impacts on heart failure mortality, and new analysis from the trial shows that patients taking the two loop diuretics also report similar improvements to symptoms and quality of life scores. The overarching chorus from CardioTwitter called for a shift in focus towards timely medication initiation and dose optimization, rather than focusing on which loop diuretics works best.

• Conformal’s LAAO Funding: Left atrial appendage occlusion device startup Conformal Medical raised a $35M Series D round (total raised $129M) to fund its pivotal CONFORM trial, support product development, and expand into new geographies. Conformal’s CLAAS System is designed to seal the left atrial appendage in patients with non-valvular Afib, and would differentiate itself by its ability to fit a broad range of LAA anatomies, its support for off-axis positioning while providing a more uniform seal, and its potential to eliminate TEE echo and avoid general anesthesia.

• Hospital Margins Break Even in April: Hospital operating margins finally broke even in April, although Kaufman Hall expects the upward momentum to be short-lived as debt levels and charity care begin climbing as states start unwinding the pandemic’s Medicaid coverage requirements. Although total expenses fell slightly month-over-month, operating revenues declined even faster, falling 5% due to volumes dropping across the board – including inpatient, outpatient, and the ED.

Monebo’s AF ECG Algorithm

Atrial fibrillation is often difficult to characterize with an automated algorithm due to the changing waveform morphology, system, or muscle noise. This is especially true given the size constraints of ambulatory devices to detect AFib. See how Monebo’s Kinetic AF ECG Algorithm overcomes these size limitations without sacrificing accuracy.

Making the Leap to Outsource Post-Processing

Interested in how to outsource cardiac image post-processing, but not sure where to start? PIA walks you through how to assess and compare vendors, understand pricing models and payment options, and outline your requirements to identify vendors who meet your clinical needs. 

The Behavioral Science Behind Change Cardiology Hemo

When Change Healthcare set out to design its next-generation Cardiology Hemo monitoring system, they put behavior science at the heart of its product strategy. See how Change’s UX designers applied its behavioral science team’s findings to improve its Hemodynamics solution to help make physicians and technicians even more efficient.